Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
The development of reliable biological markers of nigrostriatal degeneration has important implications from both experimental and clinical viewpoints, since such biomarkers could be used for diagnostic and monitoring purposes in models of parkinsonism as well as in Parkinson's disease patients. In this study, levels of the dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) were measured in the cerebrospinal fluid (CSF) of normal and parkinsonian squirrel monkeys in order to assess their reliability as indicators of nigrostriatal injury. In particular, we tested the hypothesis that these measurements may become more accurate by inhibiting catecholamine-O-methyltransferase (COMT) activity and therefore blocking the conversion of DOPAC to homovanillic acid. Oral administration of the COMT inhibitor tolcapone (2 doses of 15 mg/kg each with a 4-h interval) significantly reduced enzyme activity in the monkey brain. Tolcapone treatment enhanced CSF DOPAC concentrations in unlesioned animals (by approximately four times) as well as monkeys rendered parkinsonian after severe nigrostriatal dopaminergic injury caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Importantly, however, COMT inhibition greatly magnified the differences in CSF DOPAC levels between control and parkinsonian monkeys, since MPTP-induced DOPAC depletion was 35% in the absence vs >60% in the presence of tolcapone. Thus, tolcapone administration enhances the detection of DOPAC in the CSF and, by doing so, improves the reliability of CSF DOPAC as a marker of nigrostriatal degeneration.
Thiffault
Christine
C
The Parkinson's Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA.
Langston
J William
JW
Di Monte
Donato A
DA
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015102:3,4-Dihydroxyphenylacetic Acid / Q000134:cerebrospinal fluid* / Q000378:metabolism; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000378:metabolism; D001577:Benzophenones / Q000008:administration & dosage* / Q000378:metabolism; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D003342:Corpus Striatum / Q000473:pathology*; D004195:Disease Models, Animal; D004298:Dopamine / Q000134:cerebrospinal fluid / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid / Q000378:metabolism; D008297:Male; D019636:Neurodegenerative Diseases / Q000134:cerebrospinal fluid* / Q000473:pathology; D009596:Nitrophenols; D020734:Parkinsonian Disorders / Q000134:cerebrospinal fluid / Q000139:chemically induced / Q000473:pathology; D011237:Predictive Value of Tests; D011699:Putamen / Q000378:metabolism; D012453:Saimiri; D013378:Substantia Nigra / Q000473:pathology*; D000077867:Tolcapone
D000978:Antiparkinson Agents; D001577:Benzophenones; D015415:Biomarkers; D009596:Nitrophenols; D015102:3,4-Dihydroxyphenylacetic Acid; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000077867:Tolcapone; D002394:Catechol O-Methyltransferase; D004298:Dopamine; D006719:Homovanillic Acid